TRCT
XLO icon

Tower Research Capital (TRC)’s Xilio Therapeutics XLO Stock Holding History

Tower Research Capital (TRC)’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,101
Closed -$10.5K – 5685
2025
Q2 		$10.5K Buy
+1,101
New +$11.6K ﹤0.01% 3949
2025
Q1 		– Sell
-195
Closed -$2.61K – 5867
2024
Q4 		$2.61K Sell
195
-206
-51% -$2.83K ﹤0.01% 4809
2024
Q3 		$4.42K Buy
401
+100
+33% +$1.23K ﹤0.01% 4551
2024
Q2 		$3.99K Sell
301
-496
-62% -$7.76K ﹤0.01% 4836
2024
Q1 		$12K Sell
797
-201
-20% -$1.94K ﹤0.01% 3519
2023
Q4 		$7.69K Buy
998
+721
+260% +$14.3K ﹤0.01% 4591
2023
Q3 		$8.19K Sell
277
-37
-12% -$1.38K ﹤0.01% 4380
2023
Q2 		$11.5K Sell
314
-14
-4% -$596 ﹤0.01% 3966
2023
Q1 		$15K Buy
328
+24
+8% +$1.05K ﹤0.01% 3829
2022
Q4 		$11K Buy
304
+156
+105% +$5.26K ﹤0.01% 3886
2022
Q3 		$6K Sell
148
-292
-66% -$11.3K ﹤0.01% 5073
2022
Q2 		$18K Buy
440
+133
+43% +$7.04K ﹤0.01% 3919
2022
Q1 		$30K Buy
307
+238
+345% +$37.7K ﹤0.01% 3164
2021
Q4 		$15K Buy
+69
New +$16.5K ﹤0.01% 4015

Other funds holding XLO

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Tower Research Capital (TRC)'s XLO Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Xilio Therapeutics (XLO) in Q3 2025, closing a stake of 1,101 shares — an estimated $10.5K sold.

Tower Research Capital (TRC) first reported a position in XLO in Q4 2021 and held it in 14 quarters. The position peaked at $30K in Q1 2022. 36 funds tracked by Wall St. Rank hold XLO as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Xilio Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,101 Xilio Therapeutics shares in Q3 2025, an estimated $10.5K.
  • Tower Research Capital (TRC) first reported a position in Xilio Therapeutics in Q4 2021 and held it in 14 quarters.
  • Tower Research Capital (TRC)'s Xilio Therapeutics position peaked at $30K in Q1 2022.
  • 36 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.